Literature DB >> 23435144

Preoperative transarterial chemoembolization for hepatocellular carcinoma.

Yoji Kishi1, Akio Saiura, Junji Yamamoto, Rintaro Koga, Makoto Seki, Ryo Morimura, Ryuji Yoshioka, Norihiro Kokudo, Toshiharu Yamaguchi.   

Abstract

BACKGROUND/AIMS: The effects of transarterial chemoembolization (TACE) prior to hepatectomy for patients with hepatocellular carcinoma (HCC) are controversial.
METHODOLOGY: Clinicopathological profiles and prognosis were compared between patients who underwent hepatic resection following preoperative TACE (Group A, 69 patients) or only resection (Group B, 158 patients). Univariate and multivariate analyses were used to evaluate whether TACE influenced patient prognosis.
RESULTS: Profiles of Group A were comparable with those of Group B except for younger age, higher frequency of major hepatectomy, higher incidence of positive surgical margin, vascular invasion and poorly differentiated HCC. Overall survival was significantly worse in Group A than in Group B (5-year survival rate; 29% vs. 69%; p<0.001). A subset of patients in Group A with complete tumor necrosis by TACE showed comparable survival with Group B. Multivariate analysis revealed that preoperative TACE (hazard ratio (HR)=4.3; 95% confidential interval (CI), 2.8-6.6), non-anatomic resection (HR=1.6; 95% CI, 1.1-2.4), blood loss >1L (HR=1.8; 95% CI=1.1-2.8) and vascular invasion (HR=2.3; 95% CI=1.4-3.6) were independent predictors of poor survival. Preoperative TACE was also an independent predictor of extrahepatic metastases (odds ratio, 2.8; 95% CI=1.1-7.1).
CONCLUSIONS: Preoperative TACE should not be routinely applied for HCC.

Entities:  

Mesh:

Year:  2012        PMID: 23435144     DOI: 10.5754/hge10730

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

1.  Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1α pathway in patients with hepatocellular carcinoma.

Authors:  Weiguang Xu; Jung-Hee Kwon; Young Ho Moon; Young Bae Kim; Yun Suk Yu; Namgyu Lee; Kwan Yong Choi; Yun Soo Kim; Yong Keun Park; Bong Wan Kim; Hee Jung Wang
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-23       Impact factor: 4.553

2.  [Transarterial ablative therapy of hepatocellular carcinoma].

Authors:  A H Mahnken
Journal:  Radiologe       Date:  2014-07       Impact factor: 0.635

Review 3.  Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma.

Authors:  Yoji Kishi; Kazuaki Shimada; Satoshi Nara; Minoru Esaki; Tomoo Kosuge
Journal:  World J Hepatol       Date:  2014-12-27

4.  Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.

Authors:  Jia-Yan Ni; Hong-Liang Sun; Yao-Ting Chen; Jiang-Hong Luo; Dong Chen; Xiong-Ying Jiang; Lin-Feng Xu
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

Review 5.  Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis.

Authors:  Xingshun Qi; Lei Liu; Diya Wang; Hongyu Li; Chunping Su; Xiaozhong Guo
Journal:  Oncotarget       Date:  2015-11-03

6.  Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report.

Authors:  Hideki Yokoo; Hiroyuki Takahashi; Masahiro Hagiwara; Hiroyoshi Iwata; Koji Imai; Yoshinori Saito; Naoto Matsuno; Hiroyuki Furukawa
Journal:  World J Hepatol       Date:  2020-12-27

7.  Impact of preoperative TACE on incidences of microvascular invasion and long-term post-hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis.

Authors:  Yun Yang; Kongying Lin; Lei Liu; Youwen Qian; Yuan Yang; Shengxian Yuan; Peng Zhu; Jian Huang; Fuchen Liu; Fangming Gu; Siyuan Fu; Beige Jiang; Hui Liu; Zeya Pan; Wan Yee Lau; Weiping Zhou
Journal:  Cancer Med       Date:  2021-03-01       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.